The treatment of patients with HIV;Therapie der HIV-infektion

Deutsches Arzteblatt

Volumn 107, Issue 28-29, 2010, Pages 507-516

  Vogel, Martin ^a   Schwarze Zander, Carolynne ^a   Wasmuth, Jan Christian ^a   Spengler, Ulrich ^a   Sauerbruch, Tilman ^a   Rockstroh, Jürgen Kurt ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ATAZANAVIR PLUS RITONAVIR; CYTOCHROME P450; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ERGOTAMINE; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PEGINTERFERON; PROTON PUMP INHIBITOR; RALTEGRAVIR; RIBAVIRIN; RITONAVIR PLUS SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; EARLY DIAGNOSIS; GERMANY; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERICUM PERFORATUM; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION RISK; KAPOSI SARCOMA; LIFE EXPECTANCY; LIVER FIBROSIS; NEEDLE; PATIENT MONITORING; PNEUMOCYSTIS JIROVECI; PRACTICE GUIDELINE; REVIEW; SAFE SEX; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; TOXOPLASMOSIS; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; AIDS SERODIAGNOSIS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; FEMALE; GERMANY; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; RNA, VIRAL; YOUNG ADULT;

EID: 78049365166     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2010.0507     Document Type: Review

References (24)

1. Marcus-U, Fachgruppe 34 für HIV/AIDS u. a. sexuell oder durch Blut übertragbare Infektionen: Zum Verlauf der HIV-Epidemie in Deutschland bis Ende 2009. Epidemiologisches Bulletin 2009(48): 491-8.
2. van Sighem A, Gras L, Reiss P, Brinkman K, de Wolf F: Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS May 12. 2010; 24(10):1527-35.
3. Antiretroviral Therapy Cohort Collaboration (ART-CC) writing committee: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 37: 293-9.
4. Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342(13): 921-9.
5. Duffus WA, Weis K, Kettinger L, Stephens T, Albrecht H, Gibson JJ: Risk-based HIV testing in South Carolina health care settings failed to identify the majority of infected individuals. AIDS Patient Care STDS 2009; 23(5): 339-45.
6. LG Köln, 08-02-1995 - 25 O 308/92: Schmerzensgeld wegen HIV-Test ohne Einwilligung. NJW 1995: 1621, 2.
7. Emery S, Neuhaus JA, Phillips AN, et al.: Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008, 197(8): 1133-44. (Pubitemid 351590049)
8. Qurishi N, Kreuzberg C, Luchters G, et al.: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362 (9397): 1708-13.
9. Martin-Carbonero L, Benhamou Y, Puoti M, et al.: Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38(1): 128-33.
10. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D: Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009 10(12): 1152-9.
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2009: 1-161. Abrufbar unter: www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
12. Clumeck N, Dedes N, Pozniak A, Raffi F, EACS Executive Committee: Clinical Management and Treatment of HIV infected adults in Europe. European AIDS Clinical Society 2009:5-23. Abrufbar unter: www. europeanaidsclinicalsociety.org/guidelinespdf/1-Treatment-of-HIV-Infected- Adults.pdf.
13. Deutsch-Österreichische AIDS-Gesellschaft. Leitlinien zur antiretroviralen Therapie im Erwachsenenalter. Stand März 2010. Abrufbar unter: www.daignet.de/site-content/hiv-therapie/leitlinien-1.
14. Ballif M, Ledergerber B, Battegay M, et al.: Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS One 2009; 4(12): e8275.
15. Aldous JL, Haubrich RH: Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS 2009 Nov; 4(6): 459-66.
16. de Mendoza C, Soriano V, Perez-Olmeda M, Rodes B, Casas E, Gonzalez-Lahoz J: Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy. J Hum Virol 1999; 2: 344-9. (Pubitemid 30257651)
17. Sagir A, Oette M, Kaiser R, et al.: Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 2007; 60: 843-8.
18. De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G: Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002 Feb 11; 162(3): 355.
19. Bristol-Myers Squibb. Fachinformation Efavirenz. Berlin, 2009.
20. Infektionsmedizinisches Institut Hamburg (ifi): Interaktions-Hotline. Abrufbar unter: www.ifi-interaktions-hotline.de
21. The University of Liverpool: HIV Druginteractions. Abrufbar unter: www.hiv-druginteractions.org
22. Mocroft A, Phillips AN, Soriano V, et al.: Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005 Sep; 21(9): 743-52.
23. El-Sadr WM, Lundgren JD, Neaton JD, et al.: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355(22): 2283-96.
24. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992 Dec 18; 41(RR-17): 1-19.